Sleep Research Society

Onera Presents Its Latest Research at SLEEP 2022

Retrieved on: 
Monday, May 30, 2022
Medical Devices, Health, Clinical Trials, Research, Science, Biotechnology, Physician, ONERA, American Academy, American Academy of Sleep Medicine, SRS, Doctor of Philosophy, Charlotte Convention Center, Neuro, Health, Patient, Sleep Research Society, Associated, Quality of life, PSG, Research, FDA, Efficiency, AASM, Wireless, Polysomnography, LLC, Sleep, Pharmaceutical industry

Onera Health, a leader in transforming sleep medicine and remote monitoring, today announced that it will showcase its innovative patch-based polysomnography (PSG) system Onera STS in a late-breaking abstract at SLEEP 2022, the annual meeting of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS), which is being held from June 4-8 in Charlotte, North Carolina.

Key Points: 
  • Onera Health, a leader in transforming sleep medicine and remote monitoring, today announced that it will showcase its innovative patch-based polysomnography (PSG) system Onera STS in a late-breaking abstract at SLEEP 2022, the annual meeting of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS), which is being held from June 4-8 in Charlotte, North Carolina.
  • Oneras researcher, Flavio Raschell, PhD, will present the latest data of the ongoing clinical validation studies around the companys recently FDA-cleared Onera STS (Sleep Test System), providing further evidence on efficiency and accuracy of recorded clinical information by Oneras solution in comparison to traditional in-lab PSG testing.
  • Furthermore, Onera will exhibit its ground-breaking solution at SLEEP 2022, Booth #168, at the Charlotte Convention Center.
  • The 36th annual SLEEP meeting of the Associated Professional Sleep Societies, LLC (APSS) is a joint venture of AASM and SRS, bringing together renowned experts whose backgrounds, perspectives and experiences reflect the diversity of the fields of sleep medicine and sleep and circadian research.

Dymedix Diagnostics, INC attending the 36th Annual Sleep2022 Medical Conference in June

Retrieved on: 
Saturday, May 28, 2022
Physician, American Academy, American Academy of Sleep Medicine, Infection, Charlotte Convention Center, NC, Sleep Research Society, Associated, Polyvinylidene fluoride, Technology, New product development, INC, Safety, PVDF, Diagnosis, Collection, Pharmaceutical industry, Sleep

SHOREVIEW, Minn., May 28, 2022 /PRNewswire-PRWeb/ -- Dymedix Diagnostics, Inc is preparing to go "Back to Sleep" in Charlotte, NC for the 36th annual medical conference of the Associated Professional Sleep Societies (APSS). SLEEP 2022, is an annual conference held jointly by the American Academy of Sleep Medicine and the Sleep Research Society.

Key Points: 
  • Dymedix Diagnostics, Inc is preparing to go "Back to Sleep" in Charlotte, NC for the 36th annual medical conference of the Associated Professional Sleep Societies (APSS).
  • SLEEP 2022, is an annual conference held jointly by the American Academy of Sleep Medicine and the Sleep Research Society.
  • SHOREVIEW, Minn., May 28, 2022 /PRNewswire-PRWeb/ -- Dymedix Diagnostics, Inc is preparing to go "Back to Sleep" in Charlotte, NC for the 36th annual medical conference of the Associated Professional Sleep Societies (APSS).
  • SLEEP 2022, is an annual conference held jointly by the American Academy of Sleep Medicine and the Sleep Research Society.

Vivos Therapeutics to Present at Upcoming SLEEP 2022 Annual Meeting

Retrieved on: 
Thursday, May 26, 2022
American Academy, Company, American Academy of Sleep Medicine, Obstructive sleep apnea, OSA, U.S. Securities and Exchange Commission, SRS, VIP, Snoring, Sleep Research Society, Patient, Science, Associated, NASDAQ, Therapy, Research, Emerging technologies, Securities Exchange Act of 1934, Securities Act of 1933, Program, AASM, Dentist, Future, Drug Quality and Security Act, Risk, Vivos, Security (finance), GLOBE, Apnea–hypopnea index, Tissue, Pharmaceutical industry, Sleep

ET

Key Points: 
  • ET
    The presentation at SLEEP 2022 is a part of Vivos continuing efforts to generate and publish research and other data demonstrating how The Vivos Method can address dentofacial abnormalities and/or mild to moderate OSA and snoring in adults.
  • SLEEP 2022 provides evidence-based education to advance sleep medicines science and clinical practice, disseminating sleep and circadian research, promoting basic science translation into clinical practice and more.
  • Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for Home Sleep Testing in adults and children.
  • The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using The Vivos Method.

Inspire Medical Systems, Inc. Announces Events at SLEEP 2022, the 36th Annual Meeting of the Associated Professional Sleep Societies

Retrieved on: 
Wednesday, May 25, 2022
Cloud, Physician, American Academy, American Academy of Sleep Medicine, Obstructive sleep apnea, OSA, SRS, Machine learning, Anxiety, Patient, Investment, Associated, Sleep Research Society, Treatment, Compliance, FDA, DO, Conference, Inspiration, Implement, AASM, Technology, Polysomnography, CPAP, GLOBE, NYSE, CEO, Sleep, Pharmaceutical industry, Medicine, Airline, MD, Insomnia, Depression

SLEEP 2022 is the 36th annual meeting of the Associated Professional Sleep Societies (APSS), a joint venture of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS).

Key Points: 
  • SLEEP 2022 is the 36th annual meeting of the Associated Professional Sleep Societies (APSS), a joint venture of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS).
  • Inspire is a proud partner and sponsor of SLEEP 2022, the worlds premier forum on sleep medicine, which facilitates interactive discussions with physicians from across the globe.
  • On Tuesday, June 7, Inspire will host an educational symposium entitled Sleep Superheroes: Help Patients Succeed with Inspire.
  • An expert panel of sleep physicians will review clinical case studies focused on using Inspire programming adjustments to optimize patient outcomes.

Avadel to Present Clinical Data for FT218 at SLEEP 2022

Retrieved on: 
Thursday, May 19, 2022
American Academy, American Academy of Sleep Medicine, Narcolepsy, Excessive daytime sleepiness, Nasdaq, 2021 Essex County Council election, Patient, Associated, Sleep paralysis, Avadel Pharmaceuticals, Review, Sleep Research Society, DNS, Cataplexy, FDA, EDS, Sleep, Sodium oxybate, Hypnagogia, Safety, GLOBE, Pharmaceutical industry

DUBLIN, Ireland, May 19, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the presentation of clinical data for FT218 in nine posters at the 36th Annual Meeting of the Associated Professional Sleep Societies (APSS), the joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society being held from June 4-8, 2022 in Charlotte, NC.

Key Points: 
  • DUBLIN, Ireland, May 19, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the presentation of clinical data for FT218 in nine posters at the 36th Annual Meeting of the Associated Professional Sleep Societies (APSS), the joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society being held from June 4-8, 2022 in Charlotte, NC.
  • The presentations will highlight new interim data related to dosing and titration from the ongoing RESTORE open-label extension/switch study of FT218.
  • In March 2020, Avadel completed the REST-ON trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial, to assess the efficacy and safety of FT218 in adults with narcolepsy.
  • Avadel is currently evaluating the long-term safety and tolerability of FT218 in the open-label RESTORE clinical study.

Pajama-clad runners to drive awareness of healthy sleep with PJ5K in Charlotte

Retrieved on: 
Thursday, May 12, 2022
Yoga, Physician, Romare Bearden Park (Charlotte, North Carolina), American Academy, American Academy of Sleep Medicine, SRS, Exercise, Walkers, Science, Biology, Associated, Sleep Research Society, Charlotte Convention Center, Health, Pajamas, Sleep, Research, Awareness, AASM, Organization, GLOBE, Medicine, Pharmaceutical industry

We hope that families in the Charlotte area will join us at the community event to learn more about sleep health and enjoy an array of outdoor activities.

Key Points: 
  • We hope that families in the Charlotte area will join us at the community event to learn more about sleep health and enjoy an array of outdoor activities.
  • A joint initiative of the American Academy of Sleep Medicine and the Sleep Research Society, the SLEEP meeting brings together thousands of clinicians and scientists to discuss the latest advances in clinical sleep medicine, sleep health, and sleep and circadian science.
  • For the PJ5K, participants have the option of wearing their favorite family-friendly pajamas to draw attention to the importance of healthy sleep.
  • Established in 1975, the AASM advances sleep care and enhances sleep health to improve lives.

Beating Sleep Disorders: China's Solution to a Global Challenge

Retrieved on: 
Thursday, March 17, 2022
People, Method, Music, Insomnia, Culture, TCM, Research, Hospital, Sleep Research Society, Sleep, AI, CEO, Health, World Sleep Day, Industry, Technology, China Academy of Engineering Physics, Solution, Sleep disorder, Sport, Education, Intense, Empowerment, Aromatherapy, Pharmaceutical industry, Engineering, Tai chi, China national football team

Scientific publications on sleep health are being constantly churned out, multiplying by dozens year on year.

Key Points: 
  • Scientific publications on sleep health are being constantly churned out, multiplying by dozens year on year.
  • Professor Huang Zhili has been dedicated to the development of the products, research and education on sleep health.
  • "Chinese Sleep Research Society issues a whitepaper on sleep health every year on World Sleep Day.
  • In solving the global challenge of sleep disorder, China has demonstrated its unique wisdom and pioneering spirit.

Sleep Survey: Most Americans Understand Link Between Sufficient Sleep And Good Health; One-Third Still Don't Get Recommended Amount

Retrieved on: 
Friday, November 12, 2021
People, Rest, Public health, Korea Disease Control and Prevention Agency, Science, Sleep Research Society, Anxiety, Health, Degenerative disease, Work, Ageing, CDC, Coronavirus, Stroke, Man, National Sleep Foundation, Woman, American Academy, American Academy of Sleep Medicine, Solution, Center, Diabetes, Attention, Risk, Sleep, Obesity, Pharmaceutical industry, Health insurance, Medicine

Getting less than seven hours of sleep per 24-hour day period is known as short sleep duration.

Key Points: 
  • Getting less than seven hours of sleep per 24-hour day period is known as short sleep duration.
  • "Despite all the health experts telling us to get more sleep, Americans are still having trouble getting a good night's rest."
  • Most adults (88%) believe that quality sleep is critically important to their overall health, and two-thirds take their sleep routines seriously.
  • The biggest barrier to getting the recommended amount of sleep, according to the survey, is general stress or anxiety.

Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Retrieved on: 
Monday, November 8, 2021
NDA, Securities Exchange Act of 1934, Safety, Data, Sleep Research Society, Cataplexy, Security (finance), Knowledge, Food, Income, International, Research, Securities Act of 1933, Somnolence, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Forward-looking statement, ID, Sodium oxybate, Company, New Drug Application, U.S. Securities and Exchange Commission, GLOBE, SEC, Publication, Drug Quality and Security Act, Excessive daytime sleepiness, Webcast, Review, EDS, Nasdaq, American College of Chest Physicians, Patient, FDA, American College, Narcolepsy, Pharmaceutical industry, Risk management

ET

Key Points: 
  • ET
    DUBLIN, Ireland, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the third quarter ended September 30, 2021.
  • SG&A expenses were $21.3 million in the quarter ended September 30, 2021, compared to $8.4 million for the same period in 2020.
  • These forward-looking statements relate to our future expectations, beliefs, plans, strategies, objectives, results, conditions, financial performance, prospects, or other events.
  • The Company does not undertake any obligation to publicly update or revise our forward-looking statements, except as required by law.

Avadel Pharmaceuticals Announces Publication of Data from Pivotal Phase 3 REST-ON Trial of FT218 in Adults with Narcolepsy in SLEEP

Retrieved on: 
Monday, August 16, 2021
Regulation of tobacco by the U.S. Food and Drug Administration, Forward-looking statement, Pharming, U.S. Securities and Exchange Commission, PDUFA, Company, Sodium oxybate, Food, Securities Act of 1933, EDS, Narcolepsy, Sleep Research Society, COVID-19, Medicine, GLOBE, Risk, SEC, NDA, FDA, Security (finance), New Drug Application, Drug Quality and Security Act, Excessive daytime sleepiness, Securities Exchange Act of 1934, Somnolence, Cataplexy, Knowledge, Nasdaq, Avadel Pharmaceuticals, Safety, Review, Orphan, Pharmaceutical industry

The paper, titled Once-Nightly Sodium Oxybate (FT218) Demonstrated Improvement of Symptoms in a Phase 3 Randomized Clinical Trial in Patients With Narcolepsy, can be accessed at https://academic.oup.com/sleep/advance-article/doi/10.1093/sleep/zsab200... .

Key Points: 
  • The paper, titled Once-Nightly Sodium Oxybate (FT218) Demonstrated Improvement of Symptoms in a Phase 3 Randomized Clinical Trial in Patients With Narcolepsy, can be accessed at https://academic.oup.com/sleep/advance-article/doi/10.1093/sleep/zsab200... .
  • We believe FT218 has tremendous potential to provide clinically meaningful results for people with narcolepsy.
  • As we approach our October PDUFA date, we remain confident in the potential of FT218 and are committed to making FT218 accessible to patients, if approved.
  • Topline data from the completed randomized, double-blind, placebo-controlled REST-ON trial were announced in April 2020.